

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Plasma cytokine levels reveal deficiencies in IL-8 and gamma interferon in Long-COVID

Authors

Elizabeth S. C. P. Williams¹, Thomas B. Martins², Harry R. Hill^{2,3,4}, Mayte Coiras⁵, Kevin S. Shah³, Vicente Planelles^{1(*)}, Adam M. Spivak^{1,3(*)}

Affiliations

¹University of Utah School of Medicine, Department of Pathology, 15 North Medical Drive East, Salt Lake City, UT 84112.

²ARUP Institute for Clinical and Experimental Pathology, 1950 Circle of Hope Drive, Salt Lake City, UT 84112.

³ University of Utah School of Medicine, Department of Internal Medicine, Salt Lake City, UT 84112.

⁴University of Utah School of Medicine, Departments of Pathology and Pediatrics, Emeritus, Salt Lake City, UT 84112

⁵AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Avda. De Monforte de Lemos, 5, 28029, Madrid, Spain.

*Address correspondence to Adam.spivak@hsc.utah.edu and vicente.planelles@path.utah.edu

1 **Abstract**

2 Up to half of individuals who contract SARS-CoV-2 develop symptoms of long-COVID
3 approximately three months after initial infection. These symptoms are highly variable,
4 and the mechanisms inducing them are yet to be understood. We compared plasma
5 cytokine levels from individuals with long-COVID to healthy individuals and found that
6 those with long-COVID had 100% reductions in circulating levels of interferon gamma
7 (IFN γ) and interleukin-8 (IL-8). Additionally, we found significant reductions in levels of
8 IL-6, IL-2, IL-17, IL-13, and IL-4 in individuals with long-COVID. We propose immune
9 exhaustion as the driver of long-COVID, with the complete absence of IFN γ and IL-8
10 preventing the lungs and other organs from healing after acute infection, and reducing
11 the ability to fight off subsequent infections, both contributing to the myriad of symptoms
12 suffered by those with long-COVID.

13
14
15
16
17

18 **Keywords:** Long-COVID, PASC, IL-8, IFN γ , Immune Exhaustion, SARS-CoV-2

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

1 Introduction

2 COVID-19, caused by a novel coronavirus known as severe acute respiratory syndrome
3 coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health
4 Organization March 11th, 2020[1]. COVID-19 is responsible for 538.6 million infections
5 and over 6.3 million deaths worldwide as of June 18th, 2022[2]. For up to half of
6 individuals who contract the virus, acute SARS-CoV-2 infection is followed by persistent
7 health issues [3]. These individuals suffer a myriad of symptoms that affect their daily
8 lives, including fatigue and post-exertional malaise, respiratory and cardiac symptoms,
9 neurological symptoms, digestive symptoms, and more (Table 1)[4, 5].

10
11 Table 1. Long-COVID Symptoms

Categories:	Neurocognitive:	Respiratory:	Psychological:	Other:
Symptoms:	Brain fog	General fatigue	Post-traumatic stress disorder	Ageusia
	Dizziness	Dyspnea	Anxiety	Anosmia
	Loss of attention	Cough	Depression	Parosmia
	confusion	Throat pain	Insomnia	Skin rash
	Autonomic:	Gastrointestinal:	Musculoskeletal:	
	Chest pain	Diarrhea	Myalgias	
	Tachycardia	Abdominal pain	Arthralgias	
	palpitations	Vomiting		

12 Most commonly reported symptoms associated with long-COVID[4, 5].

13
14 Several names are in use to describe this post-viral syndrome, including long-haul
15 COVID, post-acute sequelae of SARS-CoV-2 (PASC), and long-COVID. The
16 mechanisms driving long-COVID are still poorly understood. We defined Long-COVID
17 syndrome patients as those who fulfilled one of the following criteria: (a) individuals
18 whose symptoms never resolved following acute infection; (b) individuals whose
19 COVID-19 symptoms resolved but subsequently returned; or (c) individuals who
20 developed new symptoms approximately three months after initial infection[6, 7].
21 Severity of symptoms during acute infection does not appear to predispose to
22 development of long-COVID. Both asymptomatic individuals and those hospitalized due
23 to severe complications develop long-COVID at similar rates[3, 8, 9].

24
25 Post-viral sequelae of human coronavirus (HCOV) infections have been well
26 documented [10-12]. Both the severe acute respiratory syndrome coronavirus (SARS-
27 CoV) outbreak in 2003[13-17] and the Middle Eastern respiratory syndrome coronavirus
28 (MERS-CoV) outbreak starting in 2012[18-20] caused post-viral syndromes with similar
29 symptom profiles to those experienced by individuals with long-COVID[21]. Additionally,
30 other human coronaviruses; especially HCOV 229E and HCOV NL63; that did not reach
31 pandemic status, have been implicated as the etiology of Kawasaki Syndrome[10, 11].

1 Chikungunya Virus also induces a post-viral syndrome, which presents with symptoms
2 reminiscent of rheumatoid arthritis[22-25].

3
4 Long-COVID symptomatology bears similarities to myalgic encephalomyelitis/ chronic
5 fatigue syndrome (ME/CFS). ME/CFS is characterized by 6 months or more of constant
6 or relapsing bouts of excessive fatigue, cognitive impairment, post-exertional malaise,
7 unrefreshing sleep, headaches, and neuroendocrine and immune alterations[26-30]. The
8 number of people affected by ME/CFS is growing each year, currently affecting 0.3%-
9 2.5% of the population globally, depending on the diagnostic criteria used[31, 32]. The
10 heterogeneous symptoms of ME/CFS are linked to dysregulation of multiple biological
11 systems including the immune system and inflammation[33-37], cytokines[27, 32, 38],
12 metabolism[34, 39-42], mitochondrial function[34, 39, 43], oxidative stress[34, 36],
13 apoptosis[34, 36], and circadian rhythm[34, 44]. Additionally, research into cytokine
14 levels as biomarkers for ME/CFS diagnosis or severity metrics has yielded conflicting
15 reports, for a thorough review please see Blundell *et al.* 2015[32]. There are also
16 disparate theories regarding the origin of ME/CSF including dysbiosis of one's
17 microbiome[41, 45-47], and as a post-viral syndrome following infection with Epstein
18 Barr Virus[48-51].

19
20 Based on the pro-inflammatory basis of other post viral syndromes, we hypothesized
21 that Long-COVID is caused by abnormal, sustained, elevated levels of pro-inflammatory
22 cytokines present in the blood after acute SARS-CoV-2 infection has abated. To test
23 this, we assayed plasma from 15 healthy individuals and compared it to plasma from 12
24 patients at the University of Utah's Long-COVID Clinic.

25

26 **Materials and Methods**

27

28 **Study Subjects**

29 We obtained healthy donor blood samples from individuals who were recruited under
30 University of Utah Institutional Review Board (IRB) protocol 131664. These individuals
31 were recruited from Salt Lake City, UT and the surrounding metro area between May of
32 2020 and December of 2021. For the purposes of this study, we define "healthy" as
33 individuals who were uninfected or had been infected but recovered without the
34 sequelae of long-COVID.

35

36 In the fall of 2021, the University of Utah opened a Long-COVID registry (IRB 140978).
37 Individuals attending University of Utah Comprehensive COVID clinic or self-identified
38 with Long-COVID can enroll in the registry, which includes a detailed symptom and
39 health survey and blood draw for biobanking of plasma and PBMCs at the Cellular
40 Translational Research Core (CTRC) at the University of Utah.

41

42 **Blood and Tissue Samples**

43 15 mL of total blood was collected by phlebotomy-certified research staff into two BD
44 Vacutainer EDTA Additive Blood Collection Tubes. Tubes were gently inverted 8-times
45 to mix the blood and EDTA and were then centrifuged at 150g for 20 minutes at room
46 temperature. Blood plasma was collected following centrifugation and cryopreserved in

1 sterile cryovials at -80°C. Peripheral blood mononuclear cells (PBMCs) were isolated by
2 Ficoll density gradient (Histopaque-1077, Sigma), and were cryopreserved in 1mL
3 aliquots in 80% complete culture media (endothelial cell media), 10% fetal bovine serum
4 (FBS), and 10% dimethyl sulfoxide (DMSO) in sterile cryovials at -80°C.

6 **Determination of Cytokine Concentration in Plasma**

7 The Luminex based (Luminex Corp, TX) multiplexed cytokine assay was performed
8 using a modified version of our previously published method[52, 53]. Briefly, monoclonal
9 antibodies to human IL-2, sIL-2r, IL-4, IL-6, IL-8, IL-10, TNF α (BD Biosciences, Franklin
10 Lakes, NJ), IL-13, IL-17, IFN γ (eBioscience-ThermoFisher Scientific, Waltham, MA),
11 and IL-1 β , IL-5 (R&D Systems Minneapolis, MN), IL-12 p35/p70 (Cell Sciences,
12 Newburyport MA), were covalently coupled to MagPlex microsphere particles (Luminex
13 Corporation) using a 2-step carbodiimide reaction, as previously described (Staros,
14 Wright et al. 1986). A standard curve was generated by mixing known concentrations of
15 recombinant human cytokine receptor IL-2r (R&D Systems), and recombinant human
16 cytokines IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF α and IFN γ
17 (R&D Systems). Biotinylated secondary antibodies were purchased from the following
18 sources: eBioscience-ThermoFisher Scientific (IL-1 β , IL-4, IL-6, TNF α , IL-12p70, IFN γ ,
19 IL-13, IL-17) and BD Biosciences (IL-2, IL-5, IL-8, IL-10, IL-2r). Performance parameters
20 including specimen dilution/recovery, detection capability, precision, interference due to
21 hemolysis, specimen stability, and linearity were validated following Clinical &
22 Laboratory Standards Institute (CLSI) guidelines.

24 **Statistical Analysis**

25 The individual cytokine values for the healthy and Long-COVID cohorts were analyzed
26 for statistical significance using unpaired, two-tailed, nonparametric Mann-Whitney tests
27 with Prism 9.0 (GraphPad Software, San Diego, CA, USA).

30 **Results**

31 Our long-COVID cohort included 12 individuals, who we compared to 15 matched,
32 healthy controls (Table 2). The cytokines assayed included IL-1 β , IL-2, sIL-2R, IL-4, IL-
33 5, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, IFN γ , and TNF α . Figure 1 shows the plasma
34 concentration in pg/ml of each cytokine. Individuals in the long-COVID cohort have
35 decreased levels in most cytokines tested. Most notably, individuals with long-COVID
36 have a 100% reduction
37 in plasma levels of
38 interferon gamma (IFN γ)
39 and IL-8, yielding p-
40 values of <0.0001 and
41 0.0011, respectively
42 (Figure 1).

Table 2. Cohort Demographics


	All Participants	Sex		Age Ranges
		Male	Female	
n	27	7	20	23-70
Healthy	15	7	8	27-65
Long- COVID	12	--	12	23-70

Demographics of our healthy and long-COVID cohorts.

45

1 Figure 1. Comparison of pro-inflammatory cytokines in healthy individuals and those with Long-
2 COVID

All Donors



3 Comparison of cytokines between the healthy cohort (n = 15) and the long-COVID cohort (n =
4 12). (*) p ≤ 0.05; (**) p ≤ 0.01; (***) p ≤ 0.001; (****) p ≤ 0.0001.
5
6

Table 3. Statistical Summary of Cytokine Comparison

Cytokine	Healthy		Long-COVID	% Change in Long-COVID compared to Healthy (M+F)		% Change in Long-COVID compared to Healthy (F only)	
	(M+F)	(F only)		% Change	p=	% Change	p=
n=	15	8	12				
	Median	Median	Median				
IFNγ	4.586	5.263	0.0000	-100%	<0.0001****	-100%	<0.0001****
IL-8	1.700	0.3848	0.0000	-100%	0.0011**	-100%	0.0144*
IL-6	1.248	1.317	0.3685	-70.46%	0.0016**	-72.05%	0.0062**
IL-2	2.953	3.567	1.588	-46.19%	0.0285*	-55.45%	0.0028**
IL-17	0.8802	1.024	0.4846	-44.94%	0.0082**	-52.68%	0.0191*
IL-13	9.564	13.40	5.462	-42.89%	0.0176*	-59.23%	0.0189*
IL-4	2.262	2.969	1.653	-26.92%	0.0266*	-44.32%	0.0362*
sIL-2R	229.2	205.6	174.2	-24.03%	0.1138	-15.32%	0.4269
IL-1 β	6.425	7.469	5.153	-19.8%	0.2701	-31.01%	0.0779
IL-12	2.687	2.900	2.162	-19.53%	0.1320	-25.43%	0.0788
IL-10	1.494	1.598	1.219	-18.38%	0.0717	-23.69%	0.1506
IL-5	0.5346	0.6157	0.4542	-14.71%	0.0884	-26.23%	0.0323*
TNF α	2.812	3.397	2.909	3.47%	0.7815	-14.35%	0.7201

Percent change and p-values for comparisons between the healthy cohort and the long-COVID cohort, as well as between the healthy (females only) and the long-COVID cohort.


1 In addition, individuals with long-COVID have a 70% reduction in levels of IL-6. Levels
 2 of IL-2, IL-17, and IL-13 were reduced more than 40% in individuals with long-COVID
 3 (p-values 0.0285, 0.0082, and 0.0176, respectively; Figure 1; Table 3). Individuals with
 4 long-COVID also had a reduction in levels of IL-4 (26%; p = 0.0266). Differences in
 5 plasma levels of soluble IL-2 receptor (sIL-2R), IL-1 β , IL-12, IL-10, IL-5, and TNF α
 6 between the long-covid and healthy groups were not statistically significant.

7
 8 Given that all the participants in the long-COVID group (12 out of 12) were female
 9 (Table 2), we sought to investigate whether the observed cytokine deficits in the long-
 10 COVID group were perhaps linked to biological sex. To do this, we performed two
 11 comparisons. First, we compared cytokine levels between males and females in the
 12 healthy group. These results showed that in healthy individuals, 12 out of the 13
 13 cytokines assayed were not significantly different between healthy males and females.
 14 One cytokine, IL-2, was 42% lower in healthy males than in healthy females (p =
 15 0.0367; Figure 3; Table 4).

16
 17 Secondly, we compared cytokine levels between the long-COVID group (all females)
 18 and the female participants in the healthy group (n = 8). We continue to observe a 100%
 19 reduction in IFN γ and IL-8 levels with p-values of <0.0001 and 0.0144, respectively
 20 (Figure 2). We also observed a 72% reduction in IL-6 (p = 0.0062), 55% lower levels of
 21 IL-2 (p = 0.0028), a 59% decrease in IL-13 levels (p = 0.0189), and IL-4 levels are
 22 reduced by 44% (p = 0.0362) in females with long-COVID (Figure 2; Table 3). One
 23 notable difference in the results from this female-female analysis is that the observed
 24 decrease in IL-5 levels (26%) in long-COVID females becomes statistically significant
 25 with a p-value of 0.0323, whereas the decrease between the healthy cohort when it

Figure 2. Comparison of pro-inflammatory cytokines present in healthy females and those with Long-COVID

Female Donors Only



Comparison of cytokines between the healthy cohort (n = 15) and the long-COVID cohort (n = 12). (*) $p \leq 0.05$; (**) $p \leq 0.01$; (***) $p \leq 0.001$; (****) $p \leq 0.0001$.

1
2 contains both males and
3 females and the long-
4 COVID cohort is only
5 14% and is not
6 statistically significant
7 (Figure 1; Table 3). The
8 changes observed in sIL-
9 2R, IL-1 β , IL-12, IL-10,
10 and TNF α levels remain
11 not statistically significant
12 whether the healthy
13 cohort includes the males
14 or not (Figure 2; Table 3).

Table 4. Statistical Summary of Cytokine Comparison

Cytokine	Healthy		% Change in Males compared to Females	
	Females	Males		
n=	8	7		
	Median	Median	% Change	p=
IL-2	3.567	2.04	-42.81%	0.0367*
IFN γ	5.263	3.657	-30.51%	0.2793
TNF α	3.397	2.419	-28.79%	0.6929
IL-13	13.40	9.564	-28.62%	0.0533
IL-1 β	7.469	5.479	-26.63%	0.1786
IL-5	0.6157	0.4542	-26.23%	0.1304
IL-4	2.969	2.262	-23.82%	0.2678
IL-6	1.317	1.016	-22.87%	0.9259
IL-10	1.598	1.322	-17.27%	0.8872
IL-12	2.900	2.476	-14.62%	0.1131
IL-17	1.024	0.8802	-14.04%	0.8424
sIL-2R	205.6	264.9	22.37%	0.0541
IL-8	0.3848	3.356	88.52%	0.0667

Percent change and p-values for comparisons between males and females within the healthy cohort.

20 Discussion


21
22 Upon infection with SARS-CoV-2 the innate immune system recognizes both pathogen-
23 and damage- associated molecular patterns (PAMPs and DAMPs, respectively) and
24 responds by activating the NLRP3 (NOD-, LRR-and pyrin domain-containing protein 3)
25 inflammasome[54, 55]. Monocytes and macrophages respond to PAMPs and DAMPs by
26 secreting type I IFN and the pro-inflammatory cytokines IL-1, IL-2, IL-6, IL-12, and
27 TNF α [54, 56]. To evaluate the possibility that dysregulated secretion of pro-inflammatory
28 cytokines can be observed in the context of long COVID, we measured levels of 13
29 plasma cytokines via Luminex assay in samples from 12 donors diagnosed with long-
30 COVID and compared them to 15 healthy controls (Table 2). All the statistically
31 significant differences between the long-COVID cohort and healthy controls represented
32 reductions in cytokine levels rather than the expected increases based on previous
33 studies of other post-viral syndromes (Figure 1; Table 3)[32, 57].

34
35 Pro-inflammatory cytokines have been implicated in multiple aspects of acute COVID-
36 19 pathogenesis. For example, increased levels of IL-1 β are linked to lymphopenia in
37 COVID-19 patients, presumably due to ongoing inflammation-induced pyroptosis[54,
38 58]. Macrophages express angiotensin-converting enzyme 2 (ACE2) receptors, making
39 it possible for SARS-CoV-2 to directly infect them, and, as COVID-19 severity
40 increases, activated macrophages congregate in the lungs, where even if not
41 *productively* infected, an abortive infection of macrophages by SARS-CoV-2 is sufficient
42 to induce cytokine storm[54, 59, 60]. Lastly, supporting the importance of Th17 in the
43 pathogenesis of COVID-19, is research showing that there are increased numbers of
44 Th17 cells present in blood samples of COVID-19 patients[54, 61].

45
46 The two most drastically decreased cytokines in our study were IFN γ and IL-8, each
47 reduced by 100% in our long-COVID cohort. IL-8 is produced by many cell types,

Figure 4. Comparison between healthy males and healthy females

1



1 including epithelial cells, fibroblasts, endothelial cells, macrophages, lymphocytes and
2 mast cells[62]. The secretion of IL-8 is induced in part by levels of IL-1 β . However we
3 found that there is no significant difference in IL-1 β levels between individuals with long-
4 COVID and healthy controls.

5
6 Also referred to as the neutrophil chemotactic factor, IL-8 recruits neutrophils and NK-
7 cells to sites of inflammation where they can clear infected cells and promote wound
8 healing. It is possible that the apparent lack of IL-8 in long-COVID patients may be
9 responsible for at least some of the debilitating symptoms including post-exertional
10 malaise, fatigue, persistent cough, shortness of breath and chest pain. In this scenario,
11 the acute SARS-CoV-2 infection damages the lungs, the cytokine milieu unfolds as
12 described above, recruiting cells to the site of damage where the cells can either (a)
13 help control the infection and induce a wound healing environment and the individual
14 recovers normally; or (b) the infection causes abundant cellular infiltration leading to a
15 high concentration of immune cells in a relatively small physical space, ultimately
16 causing more tissue damage, which is not efficiently repaired in the absence of IL-8.
17 Predictably, under scenario 'b' the individual remains having difficulty with oxygen
18 transfer from the lungs into the blood stream. Therefore, if the macrophages and other
19 cells that secrete IL-8 become exhausted or are otherwise incapable of secreting IL-8,
20 neutrophils will not be recruited to assist in the wound healing process in the lung once
21 the infection has been cleared[63]. Scenario 'b' therefore emerges as a potential model
22 to explain certain long-COVID complications based on lack of IL-8.

23
24 IFN γ is secreted by the innate immune natural killer cells (NK) and natural killer T cells
25 (NKT) as well as the adaptive immune CD4+ Th1 and CD8+ cytotoxic T lymphocytes
26 (CTL) after the development of antigen-specific immunity[64]. Together with IL-12, IFN γ
27 helps drive the differentiation of Th1 cells, which in turn can secrete IL-2, TNF α , and
28 IFN γ [65]. The observed lack of circulating IFN γ (Figure 1; Table 2) in the plasma of
29 COVID19 patients suggests either severe immune dysfunction or exhaustion. We
30 observed no significant difference in the levels of IL-12 (-19%), or TNF α (3%), in
31 individuals with long-COVID.

32
33 Levels of IL-2 and IL-4 were decreased by 46% and 26%, respectively, in individuals
34 with long-COVID (Figure 1; Table 2). It is possible that fewer T cells differentiated into
35 Th2 cells due to lower levels of IL-2 and IL-4, which could potentially lead to lower levels
36 of the cytokines that Th2 cells secrete (IL-4, IL-5, IL-6, IL-9, and IL-13). This scenario
37 may be supported by our data as we observed significantly lower levels of IL-4, IL-6,
38 and IL-13 in individuals with long-COVID (Figure 1; Table 2). Additionally, when we
39 compare the long-COVID cohort, which includes only females, to only the females from
40 the healthy cohort, the decrease in IL-5 between females with long-COVID and healthy
41 females becomes statistically significant ($p = 0.0323$; Figure 3; Table 2). IL-6 is involved
42 in the differentiation of Th17 cells. It is possible that the lower levels of IL-6 we observed
43 in long covid patients hindered the ability of the Th17 cells to properly differentiate.
44 Supporting this possibility, we see significantly lower levels of IL-17 in individuals with
45 long-COVID ($p = 0.0082$), the main cytokine secreted by Th17 cells.

46

1 To ensure that none of the reported differences were due to inherent sex differences we
2 compared cytokine levels between males and females within the healthy cohort. From
3 this, we only observed one significant difference, a 42% reduction of IL-2 in healthy
4 males compared to healthy females (Figure 3; Table 3). This sex-associated difference
5 in IL-2 levels between healthy males and females informed us that the most accurate
6 way to analyze IL-2 levels in our long-COVID cohort was to only consider healthy
7 female IL-2 values. Analyzed in this way, long-COVID females show a 55% reduction in
8 IL-2 levels ($p = 0.0028$; Figure 2; Table 2). The comparison including both males and
9 females in the healthy cohort is also significant, although the inherently lower values in
10 males complicate the interpretation.

11
12 Additionally, having re-analyzed the data to only include healthy females, it became
13 clear that the differences that we observe between the long-COVID females, and the
14 entire healthy population are not due solely to sex-specific differences in cytokine levels.
15 In fact, the only cytokine that differed in having statistical significance between the
16 healthy female to long-COVID female comparison, and the healthy male + female to
17 long-COVID female comparison was IL-5. The removal of the male values from the
18 analysis caused the percent change between the healthy males + females and the long-
19 COVID females to increase from 14% to 26% (between the healthy females and long-
20 COVID females) with a p-value of 0.0323 (Table 2; Figures 2 and 3).

21
22 Earlier we described the heterogeneous nature of the symptoms and cytokines
23 associated with ME/CFS. Even though the symptoms of long-COVID are thought to be
24 similar or overlapping to those of ME/CFS, when we compare our long-COVID cytokine
25 results to those from ME/CFS patients there are glaring differences. Specifically, the
26 pro-inflammatory cytokines IL-1 β , TNF α , and IL-6 tend to be reported as being elevated
27 in patients with ME/CFS[32], whereas we observed significant decreases in IL-6 levels
28 in individuals with long-COVID, and no differences in levels of IL-1 β and TNF α . A
29 detailed comparison of cytokines levels published in the context of ME/CFS[32] and our
30 long-COVID levels is provided in Supplementary Table 1.

31

32 **Conclusions**

33 Based on our results we propose that immune exhaustion perpetuates long-COVID due
34 to the seemingly complete reduction of IFN γ and IL-8, as well as significant decreases
35 in IL-2, IL-4, IL-6, IL-13, and IL-17. Identifying these and other deficiencies will provide
36 clues towards methods to intervene and possibly restore immune function in the context
37 of long-COVID. Although functional assays that test the ability of immune cells from
38 individuals with long-COVID to respond to pathogenic stimuli will be required to support
39 this theory.

40

41

42

43

44

1
2 **Funding:** This work was supported by the University of Utah Inflammation,
3 Immunology, & Infectious Diseases (3i) Initiative’s Emerging Infectious Diseases
4 Fellowship (recipient, ESCPW) and by a seed grant from the University of Utah Vice
5 President for Research and the Immunology, Inflammation, and Infectious Disease
6 Initiative (recipient, VP). VP and MC were supported by NIH GRANT 5R01-AI143567.
7

8 **CRedit author statement**

9 **Elizabeth S. C. P. Williams:** Conceptualization, methodology, formal analysis, data
10 curation, writing – original draft, visualization, funding acquisition, project administration

11 **Thomas Martins:** Investigation, resources

12 **Harry Hill:** Investigation

13 **Mayte Coiras:** Conceptualization, writing – review & editing

14 **Kevin Shah:** writing – review & editing

15 **Vicente Planelles:** Conceptualization, visualization, writing – review & editing,
16 supervision, project administration

17 **Adam Spivak:** Conceptualization, visualization, writing – review & editing
18

19 **Ethics statements**

20
21 Blood samples from donors in both our healthy and long-COVID cohorts were collected
22 from individuals who were recruited in compliance with University of Utah Institutional
23 Review Board (IRB) protocols 131664 and 140978, respectively.
24
25

26 **References**

27 [1] CDC Museum COVID-19 Timeline. <https://www.cdc.gov/museum/timeline/covid19.htm>.

28 (Accessed January 5 2022).

29 [2] COVID-19 Dashboard. <https://coronavirus.jhu.edu/map.html>. (Accessed June 18th 2022).

30 [3] C. Chen, S.R. Hauptert, L. Zimmermann, X. Shi, L.G. Fritsche, B. Mukherjee, Global Prevalence
31 of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review, J Infect Dis
32 (2022).

- 1 [4] S. Lopez-Leon, T. Wegman-Ostrosky, C. Perelman, R. Sepulveda, P.A. Rebolledo, A. Cuapio, S.
2 Villapol, More than 50 long-term effects of COVID-19: a systematic review and meta-analysis,
3 *Sci Rep* 11(1) (2021) 16144.
- 4 [5] C. Fernandez-de-Las-Penas, D. Palacios-Cena, V. Gomez-Mayordomo, M.L. Cuadrado, L.L.
5 Florencio, Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-
6 COVID): An Integrative Classification, *Int J Environ Res Public Health* 18(5) (2021).
- 7 [6] N. Nabavi, Long covid: How to define it and how to manage it, *BMJ* 370 (2020) m3489.
- 8 [7] M.J. Peluso, J. Donatelli, T.J. Henrich, Long-term immunologic effects of SARS-CoV-2
9 infection: leveraging translational research methodology to address emerging questions, *Transl
10 Res* (2021).
- 11 [8] A. Malkova, I. Kudryavtsev, A. Starshinova, D. Kudlay, Y. Zinchenko, A. Glushkova, P.
12 Yablonskiy, Y. Shoenfeld, Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form,
13 *Pathogens* 10(11) (2021).
- 14 [9] M. Peghin, A. Palese, M. Venturini, M. De Martino, V. Gerussi, E. Graziano, G. Bontempo, F.
15 Marrella, A. Tommasini, M. Fabris, F. Curcio, M. Isola, C. Tascini, Post-COVID-19 symptoms 6
16 months after acute infection among hospitalized and non-hospitalized patients, *Clinical
17 microbiology and infection : the official publication of the European Society of Clinical
18 Microbiology and Infectious Diseases* 27(10) (2021) 1507-1513.
- 19 [10] M.S.A. Samuel R. Dominguez, Mary P. Glode, Christine C. Robinson, and Kathryn V. Holmes,
20 Blinded Case-Control Study of the rELationship between Human Coronavirus NL63 ad Kawasaki
21 Syndrome, *The Journal of Infectious Diseases* 194 (2006).
- 22 [11] K. Shirato, Y. Imada, M. Kawase, K. Nakagaki, S. Matsuyama, F. Taguchi, Possible
23 involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease, *J
24 Med Virol* 86(12) (2014) 2146-53.
- 25 [12] H. Algahtani, A. Subahi, B. Shirah, Neurological Complications of Middle East Respiratory
26 Syndrome Coronavirus: A Report of Two Cases and Review of the Literature, *Case Rep Neurol
27 Med* 2016 (2016) 3502683.
- 28 [13] M.L. Catherine M. Tansey, Mark Loeb, Wayne L. Gold, Matthew P. Muller, JoAnne de Jager,
29 Jill I. Cameron, George Tomlinson, Tony Mazzulli, Sharon L. Walmsley, Anita R. Rachlis, Barbara
30 D. Mederski, Mike Silverman, Zev Shainhouse, Issa E. Ephtimios, Monica Avendano, James
31 Downey, Rima Styra, Deborah Yamamura, Marvin Gerson, Matthew B. Stanbrook, Theodore K.
32 Marras, Elizabeth J. Phillips, Noe' Zamel, Susan E. Richardson, Arthur S. Slutsky, Margaret S.
33 Herridge, One-Year Outcomes and Health Care Utilization in Survivors of Severe Acute
34 Respiratory Syndrome, *Arch Intern Med* 167 (2007).
- 35 [14] P.J. Gardner, P. Moallef, Psychological impact on SARS survivors: Critical review of the
36 English language literature, *Canadian Psychology/Psychologie canadienne* 56(1) (2015) 123-135.
- 37 [15] H. Moldofsky, J. Patcai, Chronic widespread musculoskeletal pain, fatigue, depression and
38 disordered sleep in chronic post-SARS syndrome; a case-controlled study, *BMC Neurol* 11
39 (2011) 37.
- 40 [16] H.C.C. Kang Sim, The psychological impact of SARS: a matter of heart and mind, *Journal of
41 Canadian Medical Association* 170 (2004).
- 42 [17] J.Z. KS Chan, YW Mok, YM Li, Y-N Liu, CM Chu, MS Ip, SARS: prognosis, outcome and
43 sequelae, *Respirology* 8 (2003).

- 1 [18] H. Jung, S.Y. Jung, M.H. Lee, M.S. Kim, Assessing the Presence of Post-Traumatic Stress and
2 Turnover Intention Among Nurses Post-Middle East Respiratory Syndrome Outbreak: The
3 Importance of Supervisor Support, *Workplace Health Saf* 68(7) (2020) 337-345.
- 4 [19] S. Batawi, N. Tarazan, R. Al-Raddadi, E. Al Qasim, A. Sindi, S. Al Johni, F.M. Al-Hameed, Y.M.
5 Arabi, T.M. Uyeki, B.M. Alraddadi, Quality of life reported by survivors after hospitalization for
6 Middle East respiratory syndrome (MERS), *Health Qual Life Outcomes* 17(1) (2019) 101.
- 7 [20] S.H. Lee, H.S. Shin, H.Y. Park, J.L. Kim, J.J. Lee, H. Lee, S.D. Won, W. Han, Depression as a
8 Mediator of Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory
9 Syndrome Survivors, *Psychiatry Investig* 16(1) (2019) 59-64.
- 10 [21] O. O'Sullivan, Long-term sequelae following previous coronavirus epidemics, *Clin Med*
11 (Lond) 21(1) (2021) e68-e70.
- 12 [22] A. Duvignaud, A. Fianu, A. Bertolotti, J. Jaubert, A. Michault, P. Poubeau, A. Fred, M.
13 Mechain, B.A. Gauzere, F. Favier, D. Malvy, P. Gerardin, Rheumatism and chronic fatigue, the
14 two facets of post-chikungunya disease: the TELECHIK cohort study on Reunion island,
15 *Epidemiol Infect* 146(5) (2018) 633-641.
- 16 [23] M. Foissac, E. Javelle, S. Ray, B. Guerin, F. Simon, Post-Chikungunya rheumatoid arthritis,
17 Saint Martin, *Emerg Infect Dis* 21(3) (2015) 530-2.
- 18 [24] H.A. Imad, W. Matsee, S. Kludkleeb, P. Asawapaithulsert, J. Phadungsombat, E.E.
19 Nakayama, K. Suzuki, P. Leaugwutiwong, W. Piyaphanee, W. Phumratanaprapin, T. Shioda,
20 Post-Chikungunya Virus Infection Musculoskeletal Disorders: Syndromic Sequelae after an
21 Outbreak, *Trop Med Infect Dis* 6(2) (2021).
- 22 [25] E. Javelle, A. Ribera, I. Degasne, B.A. Gauzere, C. Marimoutou, F. Simon, Specific
23 management of post-chikungunya rheumatic disorders: a retrospective study of 159 cases in
24 Reunion Island from 2006-2012, *PLoS Negl Trop Dis* 9(3) (2015) e0003603.
- 25 [26] M. Hornig, C.G. Gottschalk, M.L. Eddy, X. Che, J.E. Ukaigwe, D.L. Peterson, W.I. Lipkin,
26 Immune network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue
27 syndrome with atypical and classical presentations, *Transl Psychiatry* 7(4) (2017) e1080.
- 28 [27] J.G. Montoya, T.H. Holmes, J.N. Anderson, H.T. Maecker, Y. Rosenberg-Hasson, I.J.
29 Valencia, L. Chu, J.W. Younger, C.M. Tato, M.M. Davis, Cytokine signature associated with
30 disease severity in chronic fatigue syndrome patients, *Proc Natl Acad Sci U S A* 114(34) (2017)
31 E7150-E7158.
- 32 [28] J.G.M. Mady Hornig, Nancy G. Klimas, Susan Levine, Donna Felsenstein, Lucinda Bateman,
33 Daniel L. Peterson, C. Gunnar Gottschalk, Andrew F. Schultz, Xiaoyu Che, Meredith L. Eddy,
34 Anthony L. Komaroff, W. Ian Lipkin, Distinct plasma immune signatures in ME/CFS are present
35 early in the course of illness, *Sci Adv* (2015).
- 36 [29] U.S. Deumer, A. Varesi, V. Floris, G. Savioli, E. Mantovani, P. Lopez-Carrasco, G.M. Rosati, S.
37 Prasad, G. Ricevuti, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): An
38 Overview, *J Clin Med* 10(20) (2021).
- 39 [30] B.M. Carruthers, M.I. van de Sande, K.L. De Meirleir, N.G. Klimas, G. Broderick, T. Mitchell,
40 D. Staines, A.C. Powles, N. Speight, R. Vallings, L. Bateman, B. Baumgarten-Austrheim, D.S. Bell,
41 N. Carlo-Stella, J. Chia, A. Darragh, D. Jo, D. Lewis, A.R. Light, S. Marshall-Gradisnik, I. Mena, J.A.
42 Mikovits, K. Miwa, M. Murovska, M.L. Pall, S. Stevens, Myalgic encephalomyelitis: International
43 Consensus Criteria, *J Intern Med* 270(4) (2011) 327-38.

- 1 [31] J.B. Prins, J.W.M. van der Meer, G. Bleijenberg, Chronic fatigue syndrome, *The Lancet*
- 2 367(9507) (2006) 346-355.
- 3 [32] S. Blundell, K.K. Ray, M. Buckland, P.D. White, Chronic fatigue syndrome and circulating
- 4 cytokines: A systematic review, *Brain Behav Immun* 50 (2015) 186-195.
- 5 [33] E. Sweetman, A. Noble, C. Edgar, A. Mackay, A. Helliwell, R. Vallings, M. Ryan, W. Tate,
- 6 Current Research Provides Insight into the Biological Basis and Diagnostic Potential for Myalgic
- 7 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), *Diagnostics (Basel)* 9(3) (2019).
- 8 [34] E.R. Sweetman, Margaret; Edgar, Christina; MacKay, Angus; Vallings, Rosamund; Tate,
- 9 Warren, Changes in the transcriptome of circulating immune cells of a New Zealand cohort with
- 10 myalgic encephalomyelitis/ chronic fatigue syndrome, *International Journal of*
- 11 *Immunopathology and Pharmacology* 33 (2019).
- 12 [35] E.W. Brenu, K.J. Ashton, J. Batovska, D.R. Staines, S.M. Marshall-Gradisnik, High-throughput
- 13 sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis, *PLoS*
- 14 *One* 9(9) (2014) e102783.
- 15 [36] J.W. Gow, S. Hagan, P. Herzyk, C. Cannon, P.O. Behan, A. Chaudhuri, A gene signature for
- 16 post-infectious chronic fatigue syndrome, *BMC Med Genomics* 2 (2009) 38.
- 17 [37] C.B. Nguyen, L. Alsoe, J.M. Lindvall, D. Sulheim, E. Fagermoen, A. Winger, M. Kaarbo, H.
- 18 Nilsen, V.B. Wyller, Whole blood gene expression in adolescent chronic fatigue syndrome: an
- 19 exploratory cross-sectional study suggesting altered B cell differentiation and survival, *J Transl*
- 20 *Med* 15(1) (2017) 102.
- 21 [38] G.K. Broderick, Ben Z; Fernandes, Henrique; Fletcher, Mary Ann; Klimas, Nancy; Smith,
- 22 Frederick A; O’Gorman, Maurice RG; Vernon, Suzanne D; Taylor, Renee, cytokine expression
- 23 profiles of immune imbalance in post-mononucleosis chronic fatigue, *Journal of Translational*
- 24 *Medicine* 10 (2012).
- 25 [39] O. Fluge, O. Mella, O. Bruland, K. Risa, S.E. Dyrstad, K. Alme, I.G. Rekeland, D. Sapkota, G.V.
- 26 Rosland, A. Fossa, I. Ktoridou-Valen, S. Lunde, K. Sorland, K. Lien, I. Herder, H. Thurmer, M.E.
- 27 Gotaas, K.A. Baranowska, L.M. Bohnen, C. Schafer, A. McCann, K. Sommerfelt, L. Helgeland,
- 28 P.M. Ueland, O. Dahl, K.J. Tronstad, Metabolic profiling indicates impaired pyruvate
- 29 dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome, *JCI Insight* 1(21)
- 30 (2016) e89376.
- 31 [40] R.K. Naviaux, J.C. Naviaux, K. Li, A.T. Bright, W.A. Alaynick, L. Wang, A. Baxter, N. Nathan,
- 32 W. Anderson, E. Gordon, Metabolic features of chronic fatigue syndrome, *Proc Natl Acad Sci U S*
- 33 *A* 113(37) (2016) E5472-80.
- 34 [41] A. Proal, T. Marshall, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in the Era of
- 35 the Human Microbiome: Persistent Pathogens Drive Chronic Symptoms by Interfering With
- 36 Host Metabolism, Gene Expression, and Immunity, *Front Pediatr* 6 (2018) 373.
- 37 [42] E. Yamano, Y. Watanabe, Y. Kataoka, Insights into Metabolite Diagnostic Biomarkers for
- 38 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, *Int J Mol Sci* 22(7) (2021).
- 39 [43] C. Tomas, A. Brown, V. Strassheim, J.L. Elson, J. Newton, P. Manning, Cellular bioenergetics
- 40 is impaired in patients with chronic fatigue syndrome, *PLoS One* 12(10) (2017) e0186802.
- 41 [44] W.C. de Vega, S. Herrera, S.D. Vernon, P.O. McGowan, Epigenetic modifications and
- 42 glucocorticoid sensitivity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),
- 43 *BMC Med Genomics* 10(1) (2017) 11.

- 1 [45] N. Navaneetharaja, V. Griffiths, T. Wileman, S.R. Carding, A Role for the Intestinal
- 2 Microbiota and Virome in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)?, *J*
- 3 *Clin Med* 5(6) (2016).
- 4 [46] L. Giloteaux, J.K. Goodrich, W.A. Walters, S.M. Levine, R.E. Ley, M.R. Hanson, Reduced
- 5 diversity and altered composition of the gut microbiome in individuals with myalgic
- 6 encephalomyelitis/chronic fatigue syndrome, *Microbiome* 4(1) (2016) 30.
- 7 [47] F. Newberry, S.Y. Hsieh, T. Wileman, S.R. Carding, Does the microbiome and virome
- 8 contribute to myalgic encephalomyelitis/chronic fatigue syndrome?, *Clin Sci (Lond)* 132(5)
- 9 (2018) 523-542.
- 10 [48] M. Ruiz-Pablos, B. Paiva, R. Montero-Mateo, N. Garcia, A. Zabaleta, Epstein-Barr Virus and
- 11 the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome, *Front Immunol* 12 (2021)
- 12 656797.
- 13 [49] E. Shikova, V. Reshkova, C. Kumanova capital A, S. Raleva, D. Alexandrova, N. Capo, M.
- 14 Murovska, M.C. European Network on, Cytomegalovirus, Epstein-Barr virus, and human
- 15 herpesvirus-6 infections in patients with myalgic small ie, Cyrillicencephalomyelitis/chronic
- 16 fatigue syndrome, *J Med Virol* (2020).
- 17 [50] M.E. Ariza, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Human
- 18 Herpesviruses Are Back!, *Biomolecules* 11(2) (2021).
- 19 [51] M. Cortes Rivera, C. Mastronardi, C.T. Silva-Aldana, M. Arcos-Burgos, B.A. Lidbury, Myalgic
- 20 Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review, *Diagnostics (Basel)*
- 21 9(3) (2019).
- 22 [52] T.B. Martins, B.M. Pasi, C.M. Litwin, H.R. Hill, Heterophile antibody interference in a
- 23 multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human
- 24 serum, *Clin Diagn Lab Immunol* 11(2) (2004) 325-9.
- 25 [53] T.B. Martins, R. Burlingame, C.A. von Muhlen, T.D. Jaskowski, C.M. Litwin, H.R. Hill,
- 26 Evaluation of multiplexed fluorescent microsphere immunoassay for detection of
- 27 autoantibodies to nuclear antigens, *Clin Diagn Lab Immunol* 11(6) (2004) 1054-9.
- 28 [54] M. Patel, F. Shahjin, J.D. Cohen, M. Hasan, J. Machhi, H. Chugh, S. Singh, S. Das, T.A.
- 29 Kulkarni, J. Herskovitz, D.D. Meigs, R. Chandra, K.S. Hettie, R.L. Mosley, B.D. Kevadiya, H.E.
- 30 Gendelman, The Immunopathobiology of SARS-CoV-2 Infection, *FEMS Microbiol Rev* 45(6)
- 31 (2021).
- 32 [55] C.S. Shi, N.R. Nabar, N.N. Huang, J.H. Kehrl, SARS-Coronavirus Open Reading Frame-8b
- 33 triggers intracellular stress pathways and activates NLRP3 inflammasomes, *Cell Death Discov* 5
- 34 (2019) 101.
- 35 [56] G.a.G. Zhang, Sankar, Toll-like receptor-mediated NF-kB activation: a phylogenetically
- 36 conserved paradigm in innate immunity, *The Journal of Clinical Investigation* 107 (2001).
- 37 [57] V.A. Ryabkova, L.P. Churilov, Y. Shoenfeld, Influenza infection, SARS, MERS and COVID-19:
- 38 Cytokine storm - The common denominator and the lessons to be learned, *Clin Immunol* 223
- 39 (2021) 108652.
- 40 [58] <SSRN-id3527420.pdf>.
- 41 [59] T.a.R. Nguyen, John, The regulation of FasL expression during activation-induced cell death
- 42 (AICD), *Immunology* 103 (2001).

- 1 [60] A. Jafarzadeh, P. Chauhan, B. Saha, S. Jafarzadeh, M. Nemati, Contribution of monocytes
- 2 and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons
- 3 from SARS and MERS, and potential therapeutic interventions, *Life Sci* 257 (2020) 118102.
- 4 [61] D. Wu, X.O. Yang, TH17 responses in cytokine storm of COVID-19: An emerging target of
- 5 JAK2 inhibitor Fedratinib, *J Microbiol Immunol Infect* 53(3) (2020) 368-370.
- 6 [62] M. Baggiolini, A. Walz, S.L. Kunkel, Neutrophil-activating peptide-1/interleukin 8, a novel
- 7 cytokine that activates neutrophils, *J Clin Invest* 84(4) (1989) 1045-9.
- 8 [63] M. Metzemaekers, M. Gouwy, P. Proost, Neutrophil chemoattractant receptors in health
- 9 and disease: double-edged swords, *Cellular & molecular immunology* 17(5) (2020) 433-450.
- 10 [64] J.R. Schoenborn, C.B. Wilson, Regulation of interferon-gamma during innate and adaptive
- 11 immune responses, *Advances in immunology* 96 (2007) 41-101.
- 12 [65] A. Ray, Cytokines and their Role in Health and Disease: A Brief Overview, *MOJ Immunology*
- 13 4(2) (2016).
- 14
- 15

- 1 Supplemental Figure 1. Comparison of publications depicting cytokine fluctuation in
- 2 ME/CFS and our long-COVID cytokine results.

Cytokine	Higher in ME/CFS	Lower in ME/CFS	No Change	Total Studies	Long-COVID
Pro-inflammatory					
IL-1b	7 (28%) [1-7]	0	18 (72%) [8-25]	25	NC
TNFa	4 (15%) [1, 2, 5, 21]	0	22 (85%) [4, 6-20, 22, 24-28]	26	NC
IL-6	6 (24%) [1, 4, 6, 7, 11, 29]	2 (8%) [2, 9]	17 (68%) [8, 10, 12-16, 18, 19, 21, 23, 24, 26, 30-33]	25	Down
Anti-inflammatory					
IL-10	2 (13%) [1, 2]	1 (6%) [9]	12 (81%) [4, 6-8, 11-16, 18, 28]	15	NC
IL-13	1 (16%) [1]	0	5 (84%) [6-9, 13-15]	6	Down
Th1					
IL-2	2 (14%) [11, 13]	0	12 (86%) [1, 4, 7-9, 13-15, 18, 21, 25, 34]	14	Down
IL-12	3 (30%) [1, 7, 11]	0	7 (70%) [6, 8, 9, 13-15, 18]	10	NC
IFN γ	2 (13%) [1, 11]	1 (6%) [2]	12 (81%) [6-10, 13-15, 22, 23, 25, 28]	15	Down to 0
Th2					
IL-5	1 (14%) [7]	1 (14%) [1]	5 (72%) [8, 9, 11, 13, 14]	7	NC
IL-4	2 (18%) [1, 7]	0	9 (82%) [8, 9, 11-16, 21]	11	Down
Th17					
IL-17	0	2 (33%) [1, 9]	4 (66%) [7, 8, 13, 14]	6	Down
NK-cell attractant					
IL-8	3 (23%) [2, 6, 14]	3 (23%) [1, 7, 9]	7 (54%) [8, 11-13, 15, 16, 29]	13	Down to 0

1 Adapted from Blundell *et al.* 2015[35]. There is no agreement regarding changes in cytokine
2 levels associated with ME/CFS. Although studies that do report changes tend to report
3 cytokines as being upregulated in ME/CFS as compared to our long-COVID cytokine data
4 showing significant decreases in cytokine levels.

5

6 Supplemental References:

7

- 8 [1] S.F. Khaiboullina, K.L. DeMeirleir, S. Rawat, G.S. Berk, R.S. Gaynor-Berk, T. Mijatovic, N. Blatt,
9 A.A. Rizvanov, S.G. Young, V.C. Lombardi, Cytokine expression provides clues to the
10 pathophysiology of Gulf War illness and myalgic encephalomyelitis, *Cytokine* 72(1) (2015) 1-8.
11 [2] D. Neu, O. Mairesse, X. Montana, M. Gilson, F. Corazza, N. Lefevre, P. Linkowski, O. Le Bon,
12 P. Verbanck, Dimensions of pure chronic fatigue: psychophysical, cognitive and biological
13 correlates in the chronic fatigue syndrome, *Eur J Appl Physiol* 114(9) (2014) 1841-51.
14 [3] M. Maes, K. Ringel, M. Kubera, G. Anderson, G. Morris, P. Galecki, M. Geffard, In myalgic
15 encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is
16 associated with immuno-inflammatory pathways and bacterial translocation, *J Affect Disord*
17 150(2) (2013) 223-30.
18 [4] E.G. Lattie, M.H. Antoni, M.A. Fletcher, F. Penedo, S. Czaja, C. Lopez, D. Perdomo, A. Sala, S.
19 Nair, S.H. Fu, N. Klimas, Stress management skills, neuroimmune processes and fatigue levels in
20 persons with chronic fatigue syndrome, *Brain Behav Immun* 26(6) (2012) 849-58.
21 [5] M. Maes, F.N. Twisk, M. Kubera, K. Ringel, Evidence for inflammation and activation of cell-
22 mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS):
23 increased interleukin-1, tumor necrosis factor-alpha, PMN-elastase, lysozyme and neopterin, *J*
24 *Affect Disord* 136(3) (2012) 933-9.
25 [6] P. Scully, D.P. McKernan, J. Keohane, D. Groeger, F. Shanahan, T.G. Dinan, E.M. Quigley,
26 Plasma Cytokine Profiles in Females With Irritable Bowel Syndrome and Extra-Intestinal Co-
27 Morbidity, *Official journal of the American College of Gastroenterology | ACG* 105(10) (2010)
28 2235-2243.
29 [7] M.A. Fletcher, X.R. Zeng, Z. Barnes, S. Levis, N.G. Klimas, Plasma cytokines in women with
30 chronic fatigue syndrome, *J Transl Med* 7 (2009) 96.
31 [8] V.B. Wyller, O. Sorensen, D. Sulheim, E. Fagermoen, T. Ueland, T.E. Mollnes, Plasma cytokine
32 expression in adolescent chronic fatigue syndrome, *Brain Behav Immun* 46 (2015) 80-6.
33 [9] J.G.M. Mady Hornig, Nancy G. Klimas, Susan Levine, Donna Felsenstein, Lucinda Bateman,
34 Daniel L. Peterson, C. Gunnar Gottschalk, Andrew F. Schultz, Xiaoyu Che, Meredith L. Eddy,
35 Anthony L. Komaroff, W. Ian Lipkin, Distinct plasma immune signatures in ME/CFS are present
36 early in the course of illness, *Sci Adv* (2015).
37 [10] Y. Nakatomi, K. Mizuno, A. Ishii, Y. Wada, M. Tanaka, S. Tazawa, K. Onoe, S. Fukuda, J.
38 Kawabe, K. Takahashi, Y. Kataoka, S. Shiomi, K. Yamaguti, M. Inaba, H. Kuratsune, Y. Watanabe,
39 Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An
40 (1)(1)C-(R)-PK11195 PET Study, *J Nucl Med* 55(6) (2014) 945-50.
41 [11] M.N. Garcia, A.M. Hause, C.M. Walker, J.S. Orange, R. Hasbun, K.O. Murray, Evaluation of
42 prolonged fatigue post-West Nile virus infection and association of fatigue with elevated
43 antiviral and proinflammatory cytokines, *Viral immunology* 27(7) (2014) 327-33.

- 1 [12] T. Nakamura, S. Schwander, R. Donnelly, D.B. Cook, F. Ortega, F. Togo, Y. Yamamoto, N.S.
2 Cherniack, M. Klapholz, D. Rapoport, B.H. Natelson, Exercise and sleep deprivation do not
3 change cytokine expression levels in patients with chronic fatigue syndrome, *Clinical and*
4 *vaccine immunology : CVI* 20(11) (2013) 1736-42.
- 5 [13] G.B. Anne Liese Smylie , Henrique Fernandes , Shirin Razdan , Zachary Barnes , Fanny
6 Collado , Connie Sol , Mary Ann Fletcher and Nancy Klimas, A comparison of sex-specific
7 immune signatures in Gulf War illness and chronic fatigue syndrome, *BMC Immunology* 14
8 (2013).
- 9 [14] G.K. Broderick, Ben Z; Fernandes, Henrique; Fletcher, Mary Ann; Klimas, Nancy; Smith,
10 Frederick A; O’Gorman, Maurice RG; Vernon, Suzanne D; Taylor, Renee, cytokine expression
11 profiles of immune imbalance in post-mononucleosis chronic fatigue, *Journal of Translational*
12 *Medicine* 10 (2012).
- 13 [15] A.T. White, A.R. Light, R.W. Hughen, L. Bateman, T.B. Martins, H.R. Hill, K.C. Light, Severity
14 of symptom flare after moderate exercise is linked to cytokine activity in chronic fatigue
15 syndrome, *Psychophysiology* 47(4) (2010) 615-24.
- 16 [16] T. Nakamura, S.K. Schwander, R. Donnelly, F. Ortega, F. Togo, G. Broderick, Y. Yamamoto,
17 N.S. Cherniack, D. Rapoport, B.H. Natelson, Cytokines across the night in chronic fatigue
18 syndrome with and without fibromyalgia, *Clinical and vaccine immunology : CVI* 17(4) (2010)
19 582-7.
- 20 [17] V.A. Spence, G. Kennedy, J.J. Belch, A. Hill, F. Khan, Low-grade inflammation and arterial
21 wave reflection in patients with chronic fatigue syndrome, *Clin Sci (Lond)* 114(8) (2008) 561-6.
- 22 [18] U. Vollmer-Conna, B. Cameron, D. Hadzi-Pavlovic, K. Singletary, T. Davenport, S. Vernon,
23 W.C. Reeves, I. Hickie, D. Wakefield, A.R. Lloyd, G. Dubbo Infective Outcomes Study,
24 Postinfective fatigue syndrome is not associated with altered cytokine production, *Clin Infect*
25 *Dis* 45(6) (2007) 732-5.
- 26 [19] K.L. MacDonald, T.O. Michael, K.H. LeDell, K.E. White, C.H. Schenck, C.C. Chao, D.H. Persing,
27 R.C. Johnson, J.M. Barker, P.K. Peterson, A case-Control Study to Assess Possible Triggers and
28 Cofactors in Chronic Fatigue Syndrome, *The American Journal of Medicine* 100 (1996).
- 29 [20] C.M.A. Swanink, J.H.M.M. Vercoulen, J.M.D. Galama, M.T.L. Roos, L. Meyaard, J.v.d. Ven-
30 Jongekrijg, R.d. Nijs, G. Bleijenberg, J.F.M. Fennis, F. Miedema, Lymphocyte subsets, apoptosis,
31 and cytokines in patients with chronic fatigue syndrome, *Journal of Infectious Diseases* 173(2)
32 (1996).
- 33 [21] R. Patarca, N.G. Klimas, S. Lugtendorf, M. Antoni, M.A. Fletcher, Dysregulated Expression of
34 Tumor Necrosis Factor in Chronic Fatigue Syndrome: Interrelations with Cellular Sources and
35 Patterns of Soluble Immune Mediator Expression, *Clinical Infectious Diseases*
36 18(Supplement_1) (1994) S147-S153.
- 37 [22] A. Lloyd, S. Gandevia, A. Brockman, J. Hales, D. Wakefield, Cytokine Production and Fatigue
38 in Patients with Chronic Fatigue Syndrome and Healthy Control Subjects in Response to
39 Exercise, *Clinical Infectious Diseases* 18(Supplement_1) (1994) S142-S146.
- 40 [23] A. Linde, B. Andersson, S.B. Svenson, H. Ahrne, M. Carlsson, P. Forsberg, H. Hugo, A.
41 Karstorp, R. Lenkei, A. Lindwall, A. Loftenius, C. Säil, J. Andersson, Serum Levels of Lymphokines
42 and Soluble Cellular Receptors in Primary Epstein-Barr Virus Infection and in Patients with
43 Chronic Fatigue Syndrome, *The Journal of Infectious Diseases* 165(6) (1992) 994-1000.

- 1 [24] C.C. Chao, E.N. Janoff, S.X. Hu, K. Thomas, M. Gallagher, M. Tsang, P.K. Peterson, Altered
2 cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic
3 fatigue syndrome, *Cytokine* 3(4) (1991) 292-8.
- 4 [25] S.E. Straus, J.K. Dale, J.B. Peter, C.A. Dinarello, Circulating Lymphokine Levels in the Chronic
5 Fatigue Syndrome, *The Journal of Infectious Diseases* 160(6) (1989) 1085-1086.
- 6 [26] Y. Jammes, J.G. Steinberg, S. Delliaux, F. Bregeon, Chronic fatigue syndrome combines
7 increased exercise-induced oxidative stress and reduced cytokine and Hsp responses, *J Intern
8 Med* 266(2) (2009) 196-206.
- 9 [27] P.D. White, K.E. Nye, A.J. Pinching, T.M. Yap, N. Power, V. Vleck, D.J. Bentley, J.M. Thomas,
10 M. Buckland, J.M. Parkin, Immunological Changes After Both Exercise and Activity in Chronic
11 Fatigue Syndrome, *Journal of Chronic Fatigue Syndrome* 12(2) (2004) 51-66.
- 12 [28] J. Visser, W. Graffelman, B. Blauw, I. Haspels, E. Lentijes, E.R.d. Kloet, L. Nagelkerken, LPS-
13 induced IL-10 production in whole blood cultures from chronic fatigue syndrome patients is
14 increased but supersensitive to inhibition by dexamethasone, *Journal of Neuroimmunology* 119
15 (2001).
- 16 [29] K. Nas, R. Cevik, S. Batum, A.J. Sarac, S. Acar, S. Kalkanli, Immunologic and psychosocial
17 status in chronic fatigue syndrome, *Bratisl Lek Listy* 112(4) (2011) 208-12.
- 18 [30] M. Robinson, S.R. Gray, M.S. Watson, G. Kennedy, A. Hill, J.J. Belch, M.A. Nimmo, Plasma
19 IL-6, its soluble receptors and F2-isoprostanes at rest and during exercise in chronic fatigue
20 syndrome, *Scand J Med Sci Sports* 20(2) (2010) 282-90.
- 21 [31] U.M. Nater, L.S. Youngblood, J.F. Jones, E.R. Unger, A.H. Miller, W.C. Reeves, C. Heim,
22 Alterations in diurnal salivary cortisol rhythm in a population-based sample of cases with
23 chronic fatigue syndrome, *Psychosom Med* 70(3) (2008) 298-305.
- 24 [32] J.G. Cannon, J.B. Angel, R.W. Ball, L.W. ABAD, L.R. Fagioli, A.L. Kamaroff, Acute Phase
25 Responses and Cytokine Secretion in Chronic Fatigue Syndrome, *Journal of Clinical Immunology*
26 19 (1999).
- 27 [33] D. Buchwald, M.H. Wener, T. Pearlman, P. Kith, Markers of inflammation and immune
28 activation in chronic fatigue and chronic fatigue syndrome, *J Rheumatol* 24(2) (1997) 372-6.
- 29 [34] P.R. Cheney, S.E. Dorman, D.s. Bell, Interleukin-2 and the Chronic Fatigue Syndrome,
30 *Annals of Internal Medicine* 110 (1989).
- 31 [35] S. Blundell, K.K. Ray, M. Buckland, P.D. White, Chronic fatigue syndrome and circulating
32 cytokines: A systematic review, *Brain Behav Immun* 50 (2015) 186-195.
- 33